Innoviva Price to Book Ratio 2010-2024 | INVA

Historical price to book ratio values for Innoviva (INVA) over the last 10 years. The current price to book ratio for Innoviva as of November 20, 2024 is 1.79.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Innoviva Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2024-11-19 19.09 1.79
2024-09-30 19.31 $10.68 1.81
2024-06-30 16.40 $10.64 1.54
2023-12-31 16.04 $10.66 1.50
2023-09-30 12.99 $9.75 1.33
2023-06-30 12.73 $8.51 1.50
2023-03-31 11.25 $8.53 1.32
2022-12-31 13.25 $8.18 1.62
2024-03-31 15.24 $11.21 1.36
2022-09-30 11.61 $9.19 1.26
2022-06-30 14.76 $8.11 1.82
2022-03-31 19.35 $7.93 2.44
2021-12-31 17.25 $7.56 2.28
2021-09-30 16.71 $7.08 2.36
2021-06-30 13.41 $5.67 2.37
2021-03-31 11.95 $6.87 1.74
2020-12-31 12.39 $5.99 2.07
2020-09-30 10.45 $5.28 1.98
2020-06-30 13.98 $4.86 2.88
2020-03-31 11.76 $4.01 2.94
2019-12-31 14.16 $3.38 4.19
2019-09-30 10.54 $2.80 3.76
2019-06-30 14.56 $2.44 5.98
2019-03-31 14.03 $1.98 7.10
2018-12-31 17.45 $1.57 11.09
2018-09-30 15.24 $-1.07 -14.22
2018-06-30 13.80 $-1.53 -9.03
2018-03-31 16.67 $-2.10 -7.94
2017-12-31 14.19 $-2.38 -5.96
2017-09-30 14.12 $-2.06 -6.84
2017-06-30 12.80 $-2.71 -4.72
2017-03-31 13.83 $-3.06 -4.52
2016-12-31 10.70 $-3.26 -3.29
2016-09-30 10.99 $-3.36 -3.27
2016-06-30 10.53 $-3.26 -3.23
2016-03-31 12.59 $-3.20 -3.93
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.195B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03